Evidence map›Paper›PMID 42630219›Full record

ArticleFrontiers in neurology2026

Study on the relationship between disease progression and changes in Th17/Treg levels in patients with relapsing-remitting multiple sclerosis.

Jinshui Yang, Qian Xue, Xiaoning Wang, Aixia Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jinshui YangDepartment of Neurology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
Qian XueDepartment of Neurology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
Xiaoning WangDepartment of Neurology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
Aixia SongDepartment of Neurology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aims to investigate the relationship between disease progression and changes in Th17/Treg levels in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: This retrospective study analyzed clinical data and Th17/Treg cell levels from 130 RRMS patients and 100 non-inflammatory neurological disease controls treated between December 2021 and January 2025. Th17 cells were identified as CD4 Results: The two groups were comparable in baseline characteristics ( Conclusion: Th17/Treg imbalance may be an important mechanism underlying RRMS pathogenesis and disease progression. Modulating this balance may represent a promising therapeutic target for RRMS.

Indexed as

Disease ProgressionMultiple Sclerosis, Relapsing-RemittingTh17 CellsT-Lymphocytes, RegulatoryAdultFemaleHumansMaleMethylprednisoloneMiddle AgedRetrospective StudiesYoung AdultMethylprednisolonedisease progressionimmunomodulationrelapsing–remitting multiple sclerosisTh17 cellsTreg cells

Identifiers

PMID42630219
PMCPMC13493283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.